This review demonstrates the critical roles of interferon regulatory factors in atherosclerosis, highlighting their involvement in inflammation and lipid metabolism.
Cardiovascular diseases (CVDs) remain a leading cause of global morbidity and mortality, largely driven by the progression of atherosclerotic plaques. In atherosclerosis (AS), transcription factors and epigenetic mechanisms play pivotal roles in regulating gene expression. Interferon regulatory factors (IRFs), a family of transcription factors initially identified for their role in coordinating interferon (IFN) responses, are now recognized as critical modulators of innate and adaptive immunity. Emerging evidences highlights their involvement in inflammation, lipid metabolism, cell differentiation, cell proliferation, and programmed cell death during AS pathogenesis. This review synthesizes current knowledge on the roles and regulatory mechanisms of IRFs in AS, offering novel insights and potential therapeutic targets for AS management.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: